Drug Profile
Guanfacine extended release - Takeda
Alternative Names: Connexyn; Intuniv; Intuniv XR; S-877503; SHP 503; SPD-503Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Shire plc
- Developer Shionogi; Shire; Takeda
- Class Acetamides; Centrally-acting antihypertensives; Chlorobenzenes; Guanidines; Phenylacetates; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Attention-deficit hyperactivity disorder
- No development reported Anxiety disorders; Generalised anxiety disorder; Social phobia
Most Recent Events
- 31 Oct 2022 Takeda and Shionogi terminate the license agreement for co-development and co-promotion for guanfacine extended release in Japan
- 18 Jun 2019 Launched for Attention-deficit hyperactivity disorder (In adults) in Japan (PO)
- 13 Jun 2019 Launched for Attention-deficit hyperactivity disorder (Adjunctive treatment, In adolescents, In children) in Australia (PO)